{"id":"https://openalex.org/W3095708019","doi":"https://doi.org/10.1182/blood.v130.suppl_1.4316.4316","title":"A ROR1 Bispecific T Cell Engager for the Treatment of Chronic Lymphocytic Leukaemia Demonstrates Enhanced Function Following Ibrutinib Treatment","display_name":"A ROR1 Bispecific T Cell Engager for the Treatment of Chronic Lymphocytic Leukaemia Demonstrates Enhanced Function Following Ibrutinib Treatment","publication_year":2017,"publication_date":"2017-12-07","ids":{"openalex":"https://openalex.org/W3095708019","doi":"https://doi.org/10.1182/blood.v130.suppl_1.4316.4316","mag":"3095708019"},"language":"en","primary_location":{"id":"mag:3095708019","doi":"https://doi.org/10.1182/blood.v130.suppl_1.4316.4316","is_oa":false,"landing_page_url":"https://ashpublications.org/blood/article/130/Supplement%201/4316/72691/A-ROR1-Bispecific-T-Cell-Engager-for-the-Treatment","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Blood","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102992001","display_name":"Satyen Harish Gohil","orcid":"https://orcid.org/0000-0003-0484-991X","observed_orcids":["https://orcid.org/0000-0003-0484-991X","https://orcid.org/0000-0002-6809-6665"]},"institutions":[{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Satyen H. Gohil","raw_affiliation_strings":["University College London, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University College London, London, United Kingdom","institution_ids":["https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000231613","display_name":"Solange Rosa Paredes-Moscosso","orcid":"https://orcid.org/0000-0001-8461-2546","observed_orcids":["https://orcid.org/0000-0001-8461-2546"]},"institutions":[{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Solange Rosa Paredes-Moscosso","raw_affiliation_strings":["University College London, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0001-8461-2546","affiliations":[{"raw_affiliation_string":"University College London, London, United Kingdom","institution_ids":["https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050731553","display_name":"Micaela Harrasser","orcid":"https://orcid.org/0000-0002-2220-4683","observed_orcids":["https://orcid.org/0000-0002-2220-4683"]},"institutions":[{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Micaela Harrasser","raw_affiliation_strings":["University College London, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-2220-4683","affiliations":[{"raw_affiliation_string":"University College London, London, United Kingdom","institution_ids":["https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Mohamed El\u2010Kholy","orcid":"https://orcid.org/0000-0001-5732-1065","observed_orcids":["https://orcid.org/0000-0001-5732-1065"]},"institutions":[{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Mohamed El\u2010Kholy","raw_affiliation_strings":["University College London, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0001-5732-1065","affiliations":[{"raw_affiliation_string":"University College London, London, United Kingdom","institution_ids":["https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002366090","display_name":"Emma C. Morris","orcid":"https://orcid.org/0000-0003-4834-1130","observed_orcids":["https://orcid.org/0000-0003-4834-1130","https://orcid.org/0009-0003-6234-7878"]},"institutions":[{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Emma Morris","raw_affiliation_strings":["University College London, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0003-4834-1130","affiliations":[{"raw_affiliation_string":"University College London, London, United Kingdom","institution_ids":["https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104705974","display_name":"Amit Chunilal Nathwani","orcid":"https://orcid.org/0000-0003-1370-5950","observed_orcids":["https://orcid.org/0000-0003-1370-5950"]},"institutions":[{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Amit Nathwani","raw_affiliation_strings":["University College London, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University College London, London, United Kingdom","institution_ids":["https://openalex.org/I45129253"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5067138070","display_name":"Marco Della Peruta","orcid":"https://orcid.org/0000-0002-5580-1847","observed_orcids":["https://orcid.org/0000-0002-5580-1847"]},"institutions":[{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Marco Della Peruta","raw_affiliation_strings":["University College London, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-5580-1847","affiliations":[{"raw_affiliation_string":"University College London, London, United Kingdom","institution_ids":["https://openalex.org/I45129253"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I45129253"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"130","issue":null,"first_page":"4316","last_page":"4316"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9818999767303467,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9818999767303467,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.006800000090152025,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.002199999988079071,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ror1","display_name":"ROR1","score":0.8880000114440918},{"id":"https://openalex.org/keywords/bispecific-t-cell-engagers","display_name":"bispecific T-cell engagers","score":0.9919999837875366},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9929999709129333},{"id":"https://openalex.org/keywords/ibrutinib","display_name":"ibrutinib","score":0.9729999899864197},{"id":"https://openalex.org/keywords/t-cell-dysfunction","display_name":"T cell dysfunction","score":0.6439999938011169},{"id":"https://openalex.org/keywords/cd19","display_name":"CD19","score":0.4189999997615814},{"id":"https://openalex.org/keywords/cd20","display_name":"CD20","score":0.37400001287460327},{"id":"https://openalex.org/keywords/cd123","display_name":"CD123","score":0.36800000071525574},{"id":"https://openalex.org/keywords/cd22","display_name":"CD22","score":0.3319999873638153},{"id":"https://openalex.org/keywords/cd16","display_name":"CD16","score":0.30300000309944153},{"id":"https://openalex.org/keywords/cd18","display_name":"CD18","score":0.4519999921321869},{"id":"https://openalex.org/keywords/cd23","display_name":"CD23","score":0.44699999690055847},{"id":"https://openalex.org/keywords/cd24","display_name":"CD24","score":0.5220000147819519},{"id":"https://openalex.org/keywords/cd25","display_name":"CD25","score":0.3790000081062317}],"concepts":[{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.6002306938171387},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5559259057044983},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5198381543159485},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4619154930114746},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4438636004924774},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.41756579279899597},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.4162765443325043},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.4110690951347351},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2686295509338379},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.193618506193161},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.16431817412376404},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:3095708019","doi":"https://doi.org/10.1182/blood.v130.suppl_1.4316.4316","is_oa":false,"landing_page_url":"https://ashpublications.org/blood/article/130/Supplement%201/4316/72691/A-ROR1-Bispecific-T-Cell-Engager-for-the-Treatment","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Blood","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2936904022","https://openalex.org/W2757411938","https://openalex.org/W2942612105","https://openalex.org/W2589268751","https://openalex.org/W2795141314","https://openalex.org/W4409493855","https://openalex.org/W1613049699","https://openalex.org/W2785677301","https://openalex.org/W2615287735","https://openalex.org/W2729978555"],"abstract_inverted_index":{"Abstract":[0],"ROR1":[3,38,44,117,150,165,177,213,276,310,476,529,677],"is":[4,547,650],"expressed":[5],"on":[6,595],"a":[7,22,43,75,114,149,237,374,449,475,528,598,627,641,663],"range":[8,450],"of":[9,24,64,102,130,148,155,163,186,212,240,251,275,301,385,433,448,451,471,497,513,527,675],"solid":[10],"and":[11,21,42,84,94,105,124,135,170,201,209,306,352,380,395,402,456,486,535,588,646],"haematological":[12,172,533],"malignancies,":[13],"including":[14,356,454,622],"chronic":[15],"lymphocytic":[16],"leukaemia,":[17],"mantle":[18],"cell":[19,109,141,173,332,507,554,573,610,631],"lymphoma":[20],"subset":[23],"acute":[25],"lymphoblastic":[26],"lymphoma,":[27],"making":[28],"it":[29,365],"an":[30],"attractive":[31],"therapeutic":[32],"target.":[33],"In":[34,293,363,383,576],"keeping":[35,577],"with":[36,198,206,266,278,309,358,398,444,578],"this,":[37,386],"CAR":[39,581],"T":[40,95,133,207,241,262,304,331,371,389,491,506,553,572,582,609,630],"cells":[41,93,96,134,200,208,242,263,268,305,308,372,390,401,473,492,500,583],"antibody,":[45],"are":[46,57,176,545],"being":[47,636],"investigated":[48,145],"as":[49,509],"novel":[50],"treatments":[51],"[NCT02222688,":[52],"NCT02776917":[53],"&":[54,741,747,754],"NCT02706392].":[55],"BiTEs":[56,544],"small,":[58],"55kDa":[59],"antibody":[60],"based":[61],"therapeutics":[62],"composed":[63],"two":[65],"single":[66,238],"chain":[67],"variable":[68],"fragments":[69],"(scFv)":[70],"linked":[71],"in":[72,97,107,192,272,281,299,334,340,349,542,556,629,659,679],"tandem":[73],"by":[74,612],"flexible":[76],"linker.":[77],"One":[78],"scFv":[79],"binds":[80],"to":[81,87,226,254,326,373,408,412,467,474,502,531,666],"tumour":[82,368,614],"antigens":[83],"the":[85,88,126,146,153,161,227,249,252,273,327,338,367,498,510,525,539,673,680],"other":[86,619],"CD3":[89],"complex,":[90],"bringing":[91],"target":[92,108,255,532],"close":[98],"proximity,":[99],"facilitating":[100],"formation":[101],"cytotoxic":[103,128],"synapses":[104],"resulting":[106],"death.":[110],"We":[111,143,158,246,321],"have":[112,640],"generated":[113,591],"fully":[115],"humanised":[116],"BiTE":[118,151,166,214,219,253,277,311,515,530,653,678],"which":[119,175,543,624],"unlike":[120],"conventional":[121],"antibodies":[122],"recruits":[123],"utilises":[125],"inherent":[127],"potential":[129,147,250,526],"polyclonal":[131],"resident":[132],"does":[136],"not":[137,410,465],"require":[138],"ex":[139],"vivo":[140,193],"manipulation.":[142],"therefore":[144],"for":[152,537,549,570,655,684],"treatment":[154,205,440,568,654],"CLL.":[156,335,685],"first":[159,339],"assessed":[160,248],"efficacy":[162,348],"our":[164,670,676],"against":[167],"SKW6.4,":[168],"Jeko1":[169],"Kasumi-2":[171],"lines":[174,432],"positive,":[178],"confirming":[179,504,597],"significant":[180],"cytotoxicity":[181,298,406,517],"even":[182],"at":[183,284],"low":[184,642],"concentrations":[185],"1ng/ml":[187],"(Figure":[188,243,421,458,518],"1A).":[189],"To":[190,460],"demonstrate":[191,524,584],"potential,":[194],"mice":[195],"were":[196,264],"injected":[197],"SKW6.4":[199],"disease":[202,644,649],"established":[203],"before":[204],"5":[210],"days":[211,231],"or":[215,558],"control":[216,228],"PBS":[217],"therapy.":[218],"treated":[220],"animals":[221],"had":[222,428],"improved":[223,514,571],"survival":[224,289,317,416],"compared":[225,407],"cohort":[229,424],"(50":[230],"vs":[232,418],"18":[233],"days),":[234],"despite":[235],"only":[236],"infusion":[239],"1B).":[244],"next":[247],"primary":[256],"CLL":[257,267,282,288,307,316,354,400,415,472,499,560,593],"cells:":[258],"allogeneic":[259],"healthy":[260],"donor":[261],"co-cultured":[265],"(3:1":[269],"effector:target":[270],"ratio)":[271],"presence":[274],"resultant":[279],"decrease":[280],"viability":[283],"24":[285],"hours":[286],"(Mean":[287,315,414],"32%,":[290],"Figure":[291,319,723],"1C).":[292],"contrast,":[294],"we":[295,387,478,523],"saw":[296],"minimal":[297,647],"co-cultures":[300],"autologous":[302,399],"patient":[303],"under":[312],"identical":[313],"conditions":[314],"92%,":[318],"1D).":[320],"hypothesised":[322],"this":[323,462,579,660],"was":[324,441,464],"secondary":[325],"previously":[328],"described":[329],"multifactorial":[330],"dysfunction":[333,555],"Ibrutinib,":[337,503,596],"class":[341],"Bruton's":[342],"tyrosine":[343,620],"kinase":[344],"inhibitor,":[345],"demonstrates":[346],"impressive":[347],"front":[350],"line":[351],"relapsed/refractory":[353],"patients":[355,392,409,426,484,561,594,638,658],"those":[357],"high":[359,656],"risk":[360,657],"17p":[361,436],"deletion.":[362],"addition,":[364],"modulates":[366],"micro-environment,":[369],"skews":[370],"Th1":[375],"phenotype,":[376],"reduces":[377],"PD-1":[378],"expression":[379],"reverses":[381],"pseudo-exhaustion.":[382],"view":[384],"isolated":[388],"from":[391,482,592],"receiving":[393],"Ibrutinib":[394,413,439,468,490,567,617,634,682],"cultured":[396],"them":[397],"demonstrated":[403,493],"significantly":[404],"enhanced":[405,446,494,505],"exposed":[411],"43%":[417],"85%,":[419],"p=0.012)":[420],"1E).":[422],"This":[423],"included":[425],"who":[427],"failed":[429],"multiple":[430],"prior":[431],"therapy":[434],"and/or":[435],"deleted":[437],"cases.":[438],"also":[442],"associated":[443],"markedly":[445],"secretion":[447],"pro-inflammatory":[452],"mediators":[453],"IFN\u03b3":[455],"TNF\u03b1":[457],"1F).":[459],"ensure":[461],"effect":[463],"due":[466],"increasing":[469],"sensitivity":[470],"BiTE,":[477],"analysed":[479],"matched":[480],"samples":[481],"2":[483],"pre":[485],"post":[487,681],"treatment.":[488],"Post":[489],"killing,":[495],"irrespective":[496],"exposure":[501],"function":[508,587,611],"driving":[511],"force":[512],"mediated":[516],"1G).":[519],"Taken":[521],"together,":[522],"malignancies":[534],"highlight":[536],"CLL,":[538],"clinical":[540],"context":[541],"used":[546],"critical":[548],"effective":[550],"responses.":[551,668],"Baseline":[552],"untreated":[557],"relapsed":[559],"will":[562],"likely":[563],"limit":[564],"efficacy,":[565],"whilst":[566],"allows":[569],"effector":[574],"function.":[575],"CD19":[580],"superior":[585],"expansion,":[586],"persistence":[589],"when":[590],"global":[599],"positive":[600],"immunomodulatory":[601],"role.":[602],"Other":[603],"small":[604],"molecule":[605],"inhibitors":[606],"may":[607,625],"improve":[608],"reducing":[613],"bulk":[615],"but":[616],"inhibits":[618],"kinases":[621],"ITK,":[623],"play":[626],"role":[628],"modulation.":[632],"Despite":[633],"monotherapy":[635],"effective,":[637],"often":[639],"level":[643],"burden":[645],"residual":[648],"rarely":[651],"achieved.":[652],"situation":[661],"represents":[662],"rational":[664],"option":[665],"deepen":[667],"Overall,":[669],"data":[671],"supports":[672],"assessment":[674],"setting":[683],"Download":[695,698,708,711],":":[696,709],"high-res":[699],"image":[700,713],"(147KB)":[701],"full-size":[712],"1":[724],".":[725],"Disclosures":[735],"Gohil:":[737],"UCL":[738,744,751],"Business:":[739,745,752],"Patents":[740,746,753],"Royalties.":[742,748,755],"Nathwani:":[743],"Della":[749],"Peruta:":[750]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-11-09T00:00:00"}